TrialMultiple sclerosis (Houndmills, Basingstoke, England)2019

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Sibyl Wray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.